NasdaqGM:TNDMMedical Equipment
Is Tandem Diabetes Care (TNDM) Undervalued Following Q2 Earnings And Reaffirmed Guidance?
Why Tandem Diabetes Care Stock Is Back in Focus After Q2 Earnings
Tandem Diabetes Care (TNDM) is drawing fresh attention after its second quarter 2026 results, which showed higher sales, a smaller net loss, and reaffirmed full year revenue guidance near the US$1 billion range.
The company reported quarterly sales of US$254.56 million compared with US$240.68 million a year earlier. Net loss narrowed to US$21.17 million, with basic loss per share from continuing operations at US$0.31 versus...